MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis
L39935
Molecular testing for suspected hereditary transthyretin amyloidosis (hATTR) is covered when the patient has a clinical diagnosis of ATTR or presents with cardiac features suggestive of ATTR‑cardiomyopathy or progressive sensorimotor/autonomic neuropathy combined with supporting factors (African ancestry, a first‑degree relative with hATTR, or other guideline‑specified suggestive features). Coverage requires that patients be offered counseling, that results will inform treatment decisions, that the test targets validated guideline‑based genetic content, and that the assay has completed a technical assessment; unvalidated additional genetic content or tests lacking TA are not covered.
"Patient has a clinical diagnosis of ATTR (hereditary transthyretin amyloidosis)."
Sign up to see full coverage criteria, indications, and limitations.